Tweetable abstract #immunotherapy combinations in #sarcomatoid renal cell carcinoma: a network meta-analysis suggests #nivolumab plus #cabozantinib is the potentially preferred option in terms of efficacy in #RCC.Background: Combinations based on immune checkpoint inhibitors are the new first-line standard treatment for metastatic renal cell carcinoma. Sarcomatoid renal cell carcinoma (sRCC) has a dismal prognosis but good immunogenicity. Methods: The authors performed a network meta-analysis of Phase III randomized trials of immune checkpoint inhibitor-based combinations versus standard tyrosine kinase inhibitor monotherapy reporting data for sRCC. The endpoints were overall survival, progression-free survival and objective response rate. Results: Five trials comprising 569 sRCC patients (out of a total of 4409 metastatic renal cell carcinoma patients) were included. Nivolumab-cabozantinib was the highest ranking treatment for overall survival (p-value = 88%) and progression-free survival (p-value = 81%). Atezolizumab-bevacizumab had the highest rank for objective response rate (p-value = 80%). Conclusion: Despite some limitations, nivolumab-cabozantinib might be the preferred first-line option for sRCC in terms of efficacy.

Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis / Buti, Sebastiano; Bersanelli, Melissa; Mazzaschi, Giulia; Cattrini, Carlo; Brunelli, Matteo; Maio, Massimo Di. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - (2021). [10.2217/imt-2021-0157]

Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis

Buti, Sebastiano;Bersanelli, Melissa;Mazzaschi, Giulia;
2021

Abstract

Tweetable abstract #immunotherapy combinations in #sarcomatoid renal cell carcinoma: a network meta-analysis suggests #nivolumab plus #cabozantinib is the potentially preferred option in terms of efficacy in #RCC.Background: Combinations based on immune checkpoint inhibitors are the new first-line standard treatment for metastatic renal cell carcinoma. Sarcomatoid renal cell carcinoma (sRCC) has a dismal prognosis but good immunogenicity. Methods: The authors performed a network meta-analysis of Phase III randomized trials of immune checkpoint inhibitor-based combinations versus standard tyrosine kinase inhibitor monotherapy reporting data for sRCC. The endpoints were overall survival, progression-free survival and objective response rate. Results: Five trials comprising 569 sRCC patients (out of a total of 4409 metastatic renal cell carcinoma patients) were included. Nivolumab-cabozantinib was the highest ranking treatment for overall survival (p-value = 88%) and progression-free survival (p-value = 81%). Atezolizumab-bevacizumab had the highest rank for objective response rate (p-value = 80%). Conclusion: Despite some limitations, nivolumab-cabozantinib might be the preferred first-line option for sRCC in terms of efficacy.
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis / Buti, Sebastiano; Bersanelli, Melissa; Mazzaschi, Giulia; Cattrini, Carlo; Brunelli, Matteo; Maio, Massimo Di. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - (2021). [10.2217/imt-2021-0157]
File in questo prodotto:
File Dimensione Formato  
imt-2021-0157.pdf

non disponibili

Tipologia: Versione (PDF) editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 895.78 kB
Formato Adobe PDF
895.78 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2913807
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact